Sio Gene Therapies Inc.
SIOXDelisted Apr 12, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636050
Sio Gene Therapies Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Feb 10, 2022; 37 institutions reported holding it in 13F filings for Q4 2022, worth $8.09M in total; no superinvestor held it.
Q2 2022 vs. Q1 2022
How the institutions holding Sio Gene Therapies Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 40 | 41 | +1 |
| Shares | 18.1M | 20.7M | +2.58M (+14.2%) |
| Value | $12.1M | $7.44M | −$4.69M (−38.6%) |
New holders (8)
Institutions that held Sio Gene Therapies Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Newtyn Management, LLC | 1,415,859 | $510.0K | 0.10% |
| Jane Street Group, LLC | 92,445 | $33.0K | 0.00% |
| UBS Group AG | 55,529 | $20.0K | 0.00% |
| Boothbay Fund Management, LLC | 30,000 | $11.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 23,028 | $8.00K | 0.00% |
| Merit Financial Group, LLC | 17,750 | $6.00K | 0.00% |
| Capital Advisors, Ltd. LLC | 1,305 | $0 | 0.00% |
| Tower View Investment Management & Research LLC | 11,653 | – | – |
Sold out (7)
Institutions that held Sio Gene Therapies Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Prosight Management, LP | 670,300 | $449.0K |
| Citadel Advisors LLC | 208,065 | $139.0K |
| Two Sigma Advisers, LP | 55,838 | $37.0K |
| New York Life Investments Alternatives | 49,528 | $33.0K |
| Bank of Montreal | 10,000 | $7.00K |
| Two Sigma Securities, LLC | 10,918 | $7.00K |
| Rockefeller Capital Management L.P. | 312 | $0 |